RT Journal Article
SR Electronic
T1 A haemagglutination test for rapid detection of antibodies to SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20205831
DO 10.1101/2020.10.02.20205831
A1 Townsend, Alain
A1 Rijal, Pramila
A1 Xiao, Julie
A1 Tan, Tiong Kit
A1 Huang, Kuan-Ying A
A1 Schimanski, Lisa
A1 Huo, Jiangdong
A1 Gupta, Nimesh
A1 Rahikainen, Rolle
A1 Matthews, Philippa C
A1 Crook, Derrick
A1 Hoosdally, Sarah
A1 Street, Teresa
A1 Rudkin, Justine
A1 Stoesser, Nicole
A1 Karpe, Fredrik
A1 Neville, Matthew
A1 Ploeg, Rutger
A1 Oliveira, Marta
A1 Roberts, David J
A1 Lamikanra, Abigail A
A1 Tsang, Hoi Pat
A1 Bown, Abbie
A1 Vipond, Richard
A1 Mentzer, Alexander J
A1 Knight, Julian C
A1 Kwok, Andrew
A1 Screaton, Gavin
A1 Mongkolsapaya, Juthathip
A1 Dejnirattisai, Wanwisa
A1 Supasa, Piyada
A1 Klenerman, Paul
A1 Dold, Christina
A1 Baillie, Kenneth
A1 Moore, Shona C
A1 Openshaw, Peter JM
A1 Semple, Malcolm G
A1 Turtle, Lance CW
A1 Ainsworth, Mark
A1 Allcock, Alice
A1 Beer, Sally
A1 Bibi, Sagida
A1 Clutterbuck, Elizabeth
A1 Espinosa, Alexis
A1 Mendoza, Maria
A1 Georgiou, Dominique
A1 Lockett, Teresa
A1 Martinez, Jose
A1 Perez, Elena
A1 Sanchez, Veronica
A1 Scozzafava, Giuseppe
A1 Sobrinodiaz, Alberto
A1 Thraves, Hannah
A1 Joly, Etienne
YR 2020
UL http://medrxiv.org/content/early/2020/10/17/2020.10.02.20205831.abstract
AB Serological detection of antibodies to SARS-CoV-2 is essential for establishing rates of seroconversion in populations, detection of seroconversion after vaccination, and for seeking evidence for a level of antibody that may be protective against COVID-19 disease. Several high-performance commercial tests have been described, but these require centralised laboratory facilities that are comparatively expensive, and therefore not available universally. Red cell agglutination tests have a long history in blood typing, and general serology through linkage of reporter molecules to the red cell surface. They do not require special equipment, are read by eye, have short development times, low cost and can be applied as a Point of Care Test (POCT). We describe a red cell agglutination test for the detection of antibodies to the SARS-CoV-2 receptor binding domain (RBD). We show that the Haemagglutination Test (“HAT”) has a sensitivity of 90% and specificity of 99% for detection of antibodies after a PCR diagnosed infection. The HAT can be titrated, detects rising titres in the first five days of hospital admission, correlates well with a commercial test that detects antibodies to the RBD, and can be applied as a point of care test. The developing reagent is composed of a previously described nanobody to a conserved glycophorin A epitope on red cells, linked to the RBD from SARS-CoV-2. It can be lyophilised for ease of shipping. We have scaled up production of this reagent to one gram, which is sufficient for ten million tests, at a cost of ∼0.27 UK pence per test well. Aliquots of this reagent are ready to be supplied to qualified groups anywhere in the world that need to detect antibodies to SARS-CoV-2, but do not have the facilities for high throughput commercial tests.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAT is funded by the Medical Research Council (MR/P021336/1), Townsend-Jeantet Charitable Trust (charity number 1011770) and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002). NG is funded by the Science Engineering Research Board, Department of Science and Technology, India. PCM is funded by the Wellcome Trust (grant ref 110110Z/15/Z). DR is supported by NIHR Oxford Biomedical Research Centre. National Institute for Health Research Biomedical Research Centre Funding Scheme (to G.R.S.), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002). G.R.S. is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Oxfordshire Clinical Research Ethics Committee 08/H0606/107+5,NHS Blood and Transplant (NHSBT), ethics approval (NHSBT; RECOVERY [Cambridge East REC (ref: 20/EE/0101)] and REMAP-CAP [EudraCT 2015-002340-14], Sheffield REC, reference: 16/YH/0247]ISARIC/WHO, Clinical Characterisation Protocol for Severe Emerging Infections [Oxford REC C, reference 13/SC/0149], the Sepsis Immunomics project [Oxford REC C, reference:19/SC/0296]) and by the Scotland A Research Ethics Committee (Ref: 20/SS/0028,COVID-19 project New Delhi'IPA/2020/000077' Institutional Human Ethics Committee; Ref. no. - IHEC#128/20All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data and reagents are available on request.